Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
689 Pharmacodynamic results with talquetamab and daratumumab in patients with relapsed/refractory multiple myeloma in TRIMM-2
Compose a Response to This Article
Other responses
No responses have been published for this article.
